公开(公告)号：WO2006059867A1

公开(公告)日：2006-06-08

申请号：PCT/KR2005/004061

申请日：2005-11-30

Applicant: AMOREPACIFIC CORPORATION ,  KIM, Yeonjoon ,  KIM, Sun-young ,  HWANG, Jung Sun ,  LIM, Kyoung Min ,  PARK, Miyoung ,  KOH, Hyun Ju ,  HONG, Sa-Yong ,  SHIN, Song Seok ,  CHOI, Jin Kyu ,  MOH, Joo-Hyun ,  CHUNG, Shin ,  WOO, Byoung Young ,  KIM, Sung Il

Inventor： KIM, Yeonjoon ,  KIM, Sun-young ,  HWANG, Jung Sun ,  LIM, Kyoung Min ,  PARK, Miyoung ,  KOH, Hyun Ju ,  HONG, Sa-Yong ,  SHIN, Song Seok ,  CHOI, Jin Kyu ,  MOH, Joo-Hyun ,  CHUNG, Shin ,  WOO, Byoung Young ,  KIM, Sung Il

IPC: C07C251/44

CPC classification number: C07C317/32 ,  C07C251/44 ,  C07C255/61 ,  C07C259/18 ,  C07C323/47 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07D209/08 ,  C07D213/53 ,  C07D307/91 ,  C07D317/58 ,  C07D333/22 ,  C07D333/58 ,  C07D339/08

Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-α or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-α or PDE4.

Abstract translation: 由式（I）表示的2-环戊烯-1-酮肟衍生物或其药学上可接受的盐抑制TNF-α或PDE4的产生，因此在通过TNF-α或PDE4介导的炎症或免疫学障碍中显示出治疗效果。

公开(公告)号：WO2008069500A1

公开(公告)日：2008-06-12

申请号：PCT/KR2007/006136

申请日：2007-11-30

Applicant: AMOREPACIFIC CORPORATION ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY ,  CRYSTALGENOMICS, INC. ,  HONG, Yong Deog ,  KANG, Seung-hyun ,  KIM, Yeonjoon ,  BYOUN, Kyoung Hee ,  WOO, Byoung Young ,  PARK, Miyoung ,  JOO, Yung Hyup ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  CHEON, Younghoon ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

Inventor： HONG, Yong Deog ,  KANG, Seung-hyun ,  KIM, Yeonjoon ,  BYOUN, Kyoung Hee ,  WOO, Byoung Young ,  PARK, Miyoung ,  JOO, Yung Hyup ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  CHEON, Younghoon ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to a novel triazolopyridazine derivative or a pharmaceutically acceptable salt thereof, and an Acetyl-CoA Carboxylase2 (ACC2) comprising same as an active ingredient. The triazolopyridazine derivative of the present invention effectively inhibits the activity of ACC2 and it may be used for preventing or treating obesity, diabetes, dyslipidemia and diseases related to metabolic syndrome.

Abstract translation: 本发明涉及一种新的三唑并哒嗪衍生物或其药学上可接受的盐，以及含有作为活性成分的乙酰辅酶A羧化酶2（ACC2）。 本发明的三唑并哒嗪衍生物有效抑制ACC2的活性，可用于预防或治疗肥胖症，糖尿病，血脂异常和与代谢综合征有关的疾病。

公开(公告)号：WO2008072850A1

公开(公告)日：2008-06-19

申请号：PCT/KR2007/006192

申请日：2007-12-03

Applicant: AMOREPACIFIC CORPORATION ,  CRYSTALGENOMICS, INC. ,  INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY of Yonsei University ,  JOO, Yung Hyup ,  KANG, Seung-hyun ,  HONG, Yong Deog ,  KIM, Yeonjoon ,  BYOUN, KyoungHee ,  WOO, Byoung Young ,  PARK, Miyoung ,  HA, Jun Yong ,  KOH, Hyunju ,  LIM, Kyung Min ,  KIM, Chae-wook ,  LEE, Byoung-seok ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  LEE, Kyung Ho ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

Inventor： JOO, Yung Hyup ,  KANG, Seung-hyun ,  HONG, Yong Deog ,  KIM, Yeonjoon ,  BYOUN, KyoungHee ,  WOO, Byoung Young ,  PARK, Miyoung ,  HA, Jun Yong ,  KOH, Hyunju ,  LIM, Kyung Min ,  KIM, Chae-wook ,  LEE, Byoung-seok ,  KIM, Jung Ju ,  JANG, Doo Ok ,  TAE, Jinsung ,  SHIN, Dongkyu ,  KIM, Yong Eun ,  LEE, Kyung Ho ,  LEE, Jae Il ,  HYUN, Young-Lan ,  RO, Seonggu ,  CHO, Joong Myung

IPC: C07D413/14 ,  C07D251/72 ,  C07D251/02 ,  C07D215/00 ,  C07D265/00 ,  C07D207/00 ,  C07D221/00 ,  A61K31/47 ,  A61K31/53 ,  A61P7/00

CPC classification number: C07D405/14 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to a novel triazine derivative or a pharmaceutically acceptable salt thereof, and an Acetyl-CoA Carboxylase (ACC) comprising same as an active ingredient. The triazine derivative of the present invention effectively inhibits the activity of ACC and it may be used for preventing or treating obesity, diabetes, dyslipidemia and diseases related to metabolic syndrome.

Abstract translation: 本发明涉及一种新型的三嗪衍生物或其药学上可接受的盐，以及含有作为活性成分的乙酰辅酶A羧化酶（ACC）。 本发明的三嗪衍生物有效抑制ACC的活性，可用于预防或治疗肥胖症，糖尿病，血脂异常和与代谢综合征有关的疾病。